reports
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 20 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 11 November 2024, Novo Nordisk will r...
- ABGSC Healthcare Research
- Morten Larsen
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adult...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised people...
The acquisition of Catalent by Novo Holdings, and the related acquisit...
The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed Bagsværd, Denmark, 18 December 2024 — Today, Novo Nordisk completed its acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalisation of Novo Holdings’ acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US). The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information...
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 16 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 11 November 2024, Novo Nordisk will r...
- ABGSC Healthcare Research
- Morten Larsen
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and th...
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S’s pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well ...
Novo Nordisk A/S: European regulatory authority adopts positive opinio...
Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events Bagsværd, Denmark, 12 December 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly subcutaneous semaglutide) label to reflect data from the FLOW kidney outcomes trial. The FLOW trial assessed the risk reduction from Ozempic® therapy in chronic kidney disease-related events, ...
- Emira Sagaama
- Ghada Ben Sedrine
- Nicolas David
- Oddo Sustainability Team
- Thomas Zlowodzki
SOP SOPRA STERIA GROUP SA
ATO ATOS SE
ROG ROCHE HOLDING LTD
ACN ACCENTURE PLC CLASS A
NOVN NOVARTIS AG
LONN LONZA GROUP AG
INF INFOTEL SA
SQI SQLI SA
SWP SWORD GROUP SE
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
AUB AUBAY SA
ATE ALTEN SA
ZAL ZALANDO SE
GRF GRIFOLS S.A. CLASS A
SAN SANOFI
CAP CAPGEMINI SE
TLX TALANX AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
ITX INDUSTRIA DE DISENO TEXTIL S.A.
BC BRUNELLO CUCINELLI S.P.A.
IDR INDRA SISTEMAS S.A. CLASS A
GRF.P GRIFOLS S.A. PREF CLASS B
AZN ASTRAZENECA PLC
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALG ALLEGRO.EU SA
NA9 NAGARRO
EXN EXCLUSIVE NETWORKS SA
GSK GSK PLC
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
- Emira Sagaama
- Ghada Ben Sedrine
- Nicolas David
- Oddo Sustainability Team
- Thomas Zlowodzki
SOP SOPRA STERIA GROUP SA
ATO ATOS SE
ROG ROCHE HOLDING LTD
ACN ACCENTURE PLC CLASS A
NOVN NOVARTIS AG
LONN LONZA GROUP AG
INF INFOTEL SA
SQI SQLI SA
SWP SWORD GROUP SE
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
AUB AUBAY SA
ATE ALTEN SA
ZAL ZALANDO SE
GRF GRIFOLS S.A. CLASS A
SAN SANOFI
CAP CAPGEMINI SE
TLX TALANX AG
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
TIETO TIETOEVRY OYJ
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
ITX INDUSTRIA DE DISENO TEXTIL S.A.
BC BRUNELLO CUCINELLI S.P.A.
IDR INDRA SISTEMAS S.A. CLASS A
GRF.P GRIFOLS S.A. PREF CLASS B
AZN ASTRAZENECA PLC
ECONT ECONOCOM GROUP SE CLASS D
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
ALG ALLEGRO.EU SA
NA9 NAGARRO
EXN EXCLUSIVE NETWORKS SA
GSK GSK PLC
IOS IONOS GROUP SE
NOVO B NOVO NORDISK A/S
- Team Pharma
- Team Pharma
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 9 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 11 November 2024, Novo Nordisk will re...
The European Commission approves the acquisition of Catalent by Novo H...
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S’ acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk’s subsequent acquisition of three manufacturing sites from Novo Holdings A/S. The agreement to acquire the three manufacturing sites was announced on 5 February 2024. Fo...
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 2 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 11 November 2024, Novo Nordisk will re...
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 25 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 11 November 2024, Novo Nordisk will r...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 19 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and ...
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 18 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme initiated 11 November 2024, Novo Nordisk will r...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 13 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and ...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, exe...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 12 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executive...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.